Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy

A Review of Granisetron, 5-Hydroxytryptamine3 Receptor Antagonists, and Other Antiemetics

(2010) Eric S Hsu   AMERICAN JOURNAL OF THERAPEUTICS

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Polymorphism inHTR3Dshows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy

(2010) Christian Hammer et al.   PHARMACOGENOMICS

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

(2009) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Chemotherapy-Induced Nausea and Vomiting

(2008) Lisa Lohr   CANCER JOURNAL

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy

(2008) P. A. Fasching et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY